Oncology news from FierceBiotech
NewsNanotech investment will have payoff
A recent report by Credit Suisse analysts found that investing in medical nanotechnology could have a real payoff in the coming years. Oncology and CNS diseases in particular will be a target for Read more...
CytRx inks deal to buy Innovive in $21M acquisition
CytRx has inked a deal to buy Innovive Pharmaceuticals, adding its four experimental oncology therapies to its pipeline. The combined company will own a 49% interest in RXi Pharmaceuticals. The deal Read more...
BMS buys Kosan for $190M
Bristol-Myers Squibb is adding two oncology drugs to its pipeline with the acquisition of Kosan Biosciences. The company is paying $5.50 per share in cash for Kosan and gains two anticancer agents: Read more...
Sonus, OncoGenex to merge
Bothell, WA-based Sonus Pharmaceuticals is merging with Canada's OncoGenex Technologies and will operate under the name OncoGenex Pharmaceuticals. OncoGenex's CEO Scott Cormack will head up the new Read more...
JapanBridge pays $26M for ProStrakan patch
JapanBridge is paying $26 million in upfront and milestone payments for the rights to develop and commercialize Sancuso, a transdermal patch for the prevention of chemotherapy-induced nausea and Read more...
Pfizer gets new cancer team to advance key drugs
With the clock ticking on its patent for Lipitor, Pfizer has turned to a group of new executives to Read more...
ASCO braces for massive data dump before meeting
The analysts devoted to tracking biotech companies in the oncology arena will have their hands full tomorrow night at 9 p.m. EST. That's when ASCO will do an online data dump in advance of its annual Read more...
EUSA Pharma spins off assets as it narrows focus
The transatlantic EUSA Pharma has spun off its monoclonal antibody research operation along with a development program for leukemia as it narrows its focus to late-stage drug development and Read more...
SPOTLIGHT: Biocon establishing R&D sub
India's Biocon says it will transfer four molecules to a new R&D subsidiary, resisting a trend in the subcontinent of spinning off R&D into a new company. Its researchers are working on new Read more...
Genzyme gets biosimilar rejection, builds R&D plant
The FDA have given a thumbs down to Genzyme's request for permission to sell its Pompe disease drug Read more...
| Press ReleasesPRESS RELEASE: Pfizer Oncology Initiates Global Phase III Trial to Evaluate Sunitinib Malate Combined with Erlotinib Pfizer Oncology Initiates Global Phase III Trial to Evaluate Sunitinib Malate Combined with Erlotinib in Advanced Non-Small Cell Lung Cancer SEOUL, Korea -- Sep 6, 2007 - Pfizer announced today the Read more... |
Get more Oncology coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets